Factor Xa │ Inhibitor
Activated Factor X (Factor Xa) is the central point of amplification, as 1 molecule catalyses the formation of approximately 1,000 thrombin molecules.
Activated Factor X (Factor Xa) is a central component of the prothrombinase complex, which converts large amounts of prothrombin (Factor II) to thrombin, described as the “thrombin burst”. One molecule of Factor Xa catalyses the formation of approximately 1,000 thrombin molecules.25, 26, 27
Activated Factor X (Factor Xa) is a central component of the prothrombinase complex, which converts large amounts of prothrombin (Factor II) to thrombin, described as the “thrombin burst”. One molecule of Factor Xa catalyses the formation of approximately 1,000 thrombin molecules.25, 26, 27
Factor Xa Inhibitor
Inhibition of Factor Xa prevents prevents pathological clot formation (thrombosis)effectively. In addition, inhibition of Factor Xa has an antithrombotic effect, without affecting existing thrombin levels. This remaining thrombin should be sufficient to ensure primary haemostasis, resulting in a favourable safety margin.26, 28
Xarelto® is the first direct inhibitor of Factor Xa available for clinical use. It is leading a new generation of Factor Xa–inhibiting drugs under development designed to meet the clinical need for improved antithrombotic therapy. It is approved in the European Union for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.1, 26
Xarelto® is the first direct inhibitor of Factor Xa available for clinical use. It is leading a new generation of Factor Xa–inhibiting drugs under development designed to meet the clinical need for improved antithrombotic therapy. It is approved in the European Union for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.1, 26
See also: Oral Anticoagulant
See also: Blood Clot Symptoms
- 25 - Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1(7):1504-1514.
- 26 - Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27(6):1238-1247.
- 27 - Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis. 2008;25(1):52-60.
- 28 - Leadley RJ Jr. Coagulation factor Xa inhibition: biological background and rationale. Curr Top Med Chem. 2001;1(2):151-159.
- 1 - Xarelto® (rivaroxaban) Summary of Product Characteristics as approved by the European Commission.
